Filippo Giancotti: Publications

Okada T, Sinha S, Esposito I, Schiavon G, López-Lago MA, Su W, Pratilas CA, Abele C, Hernandez JM, Ohara M, Okada M, Viale A, Heguy A, Socci ND, Sapino A, Seshan VE, Long S, Inghirami G, Rosen N, Giancotti FG. (2015). The Rho Gtpase Rnd1 supresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling. Nat Cell Biol; Jan;17(1):81-94.

Gao H, Chakraborty G, Lee-Lim AP, Mavrakis KJ, Wendel HG, Giancotti FG. (2014). Forward genetic screens in mice uncover mediators and suppressors of metastatic reactivation. Proc. Natl. Acad. Sci; Nov. 18; 111(46):16532-7.

Li W, Cooper J, Zhou L, Yang C, Erdjument-Bromage H, Zagzag D, Snuderl M, Ladanyi M, Hanneman O, Zhou P, Karajannis M, Giancotti FG. (2014). Merlin/NF2 loss-driven tumorigenesis linked to CRL4DCAF1-mediated inhibition of the Hippo pathway kinases Lats1 and 2 in the nucleus. Cancer Cell; July 14;26(1)48-60. [PMID 25026211]

Yoshioka T, Otero J, Chen Y, Kim YM, Koutcher JA, Satagopan J, Reuter V, Carver B, de Stanchina E, Enomoto K, Greenberg NM, Scardino PT, Scher HI, Sawyers CL, Giancotti FG. (2013). B4 Integrin signaling induces expansion of prostate tumor progenitors. J. Clin. Inves. Feb 1;123(2):682-99.

Gao H, Chakraborty G, Lee-Lim AP, Mo Q, Decker M, Vonica A, Shen R, Brogi E, Brivanlou AH, Giancotti FG. (2012). The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell Aug 17;150(4):764-79

Li W*, You L*, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini M, Hanemann CO, Long SB, Erdjument-Bromage H, Zhou P, Tempst P, Giancotti FG. (2010). Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 140(4):477-90. [*equal conttributions] [cover article; Must Read F1000]

López-Lago MA, Okada T, Murillo MM, Socci N, Giancotti FG. (2009). Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol. 29(15):4235-49.

Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G, Giancotti FG. (2006). β4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell. 126(3):489-502 [Preview by Muthuswamy, S.K. in Cell 126:443-445, 2006; Preview by Carraway, K.L. III, and Sweeney, C. in Cancer Cell 10(2):93-95, 2006; News and Views by Walker and Brugge in Nat Cell Biol 8:1220-1222, 2006; Exceptional F1000].

Okada T, López-Lago M, Giancotti FG. (2005). Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol. 171(2):361-71. [Must Read F1000]

Nikolopoulos SN, Blaikie P, Yoshioka T, Guo W, Puri C, Tacchetti C, Giancotti FG. (2005). Targeted deletion of the integrin β4 signaling domain suppresses laminin-5-dependent nuclear entry of mitogen-activated protein kinases and NF-kappaB, causing defects in epidermal growth and migration. Mol Cell Biol. 25(14):6090-102.

Nikolopoulos SN, Blaikie P, Yoshioka T, Guo W, Giancotti FG.  (2004). Integrin β4 signaling promotes tumor angiogenesis. Cancer Cell. 6(5):471-83.

Gagnoux-Palacios L, Dans M, van't Hof W, Mariotti A, Pepe A, Meneguzzi G, Resh MD, Giancotti FG. (2003). Compartmentalization of integrin α6β4 signaling in lipid rafts. J Cell Biol. 162(7):1189-96.

Weaver VM, Lelièvre S, Lakins JN, Chrenek MA, Jones JC, Giancotti F, Werb Z, Bissell MJ. (2002). β4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell. 2002, 2(3):205-16 [Preview by Jacks and Weinberg in Cell 11:923-925; News and Views by Yamada and Clark in Nature 419:790-791, 2002; Must Read F1000].

Klein S, de Fougerolles AR, Blaikie P, Khan L, Pepe A, Green CD, Koteliansky V, Giancotti FG. (2002). α5β1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation. Mol Cell Biol. 22(16):5912-22.

Mariotti A, Kedeshian PA, Dans M, Curatola AM, Gagnoux-Palacios L, Giancotti FG. (2001). EGF-R signaling through Fyn kinase disrupts the function of integrin α6β4 at hemidesmosomes: role in epithelial cell migration and carcinoma invasion. J Cell Biol. 155(3):447-58.

Mettouchi A, Klein S, Guo W, López-Lago M, Lemichez E, Westwick JK, Giancotti FG. (2001). Integrin-specific activation of Rac controls progression through the G(1) phase of the cell cycle. Mol Cell. 2001, 8(1):115-27 [Previews by Ridley, A.J. in Dev. Cell 1(2):160-161, 2001; Research Roundup by Powledge, T.M. in J. Cell Biol. 154:677; Must Read F1000].

Dans M, Gagnoux-Palacios L, Blaikie P, Klein S, Mariotti A, Giancotti FG.Tyrosine phosphorylation of the β4 integrin cytoplasmic domain mediates Shc signaling to extracellular signal-regulated kinase and antagonizes formation of hemidesmosomes. (2001). J Biol Chem. 2001, 276(2):1494-502.

Barberis L, Wary KK, Fiucci G, Liu F, Hirsch E, Brancaccio M, Altruda F, Tarone G, Giancotti FG. (2000). Distinct roles of the adaptor protein Shc and focal adhesion kinase in integrin signaling to ERK. J Biol Chem. 275(47):36532-40.

Oktay M, Wary KK, Dans M, Birge RB, Giancotti FG. (1999). Integrin-mediated activation of focal adhesion kinase is required for signaling to Jun NH2-terminal kinase and progression through the G1 phase of the cell cycle. J Cell Biol. 145(7):1461-69.

Wary KK, Mariotti A, Zurzolo C, Giancotti FG. (1998). A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell. 94(5):625-34.

Murgia C, Blaikie P, Kim N, Dans M, Petrie HT, Giancotti FG. (1998). Cell cycle and adhesion defects in mice carrying a targeted deletion of the integrin β4 cytoplasmic domain. EMBO J. 17(14):3940-51.

Mainiero F, Murgia C, Wary KK, Curatola AM, Pepe A, Blumemberg M, Westwick JK, Der CJ, Giancotti FG. (1997). The coupling of α6β4 integrin to Ras-MAP kinase pathways mediated by Shc controls keratinocyte proliferation. EMBO J. 16(9):2365-75.

Wary KK, Mainiero F, Isakoff SJ, Marcantonio EE, Giancotti FG. (1996). The adaptor protein Shc couples a class of integrins to the control of cell cycle progression. Cell. 87(4):733-43.

Mainiero F, Pepe A, Yeon M, Ren Y, Giancotti FG. (1996). The intracellular functions of α6β4 integrin are regulated by EGF. J Cell Biol. 134(1):241-53.

Mainiero F, Pepe A, Wary KK, Spinardi L, Mohammadi M, Schlessinger J, Giancotti FG. (1995). Signal transduction by the α6β4 integrin: distinct β4 subunit sites mediate recruitment of Shc/Grb2 and association with the cytoskeleton of hemidesmosomes. EMBO J. 14(18):4470-81.

Spinardi L, Ren YL, Sanders R, Giancotti FG. (1993). The β4 subunit cytoplasmic domain mediates the interaction of α6β4 integrin with the cytoskeleton of hemidesmosomes. Mol Biol Cell. 4(9):871-84.

Giancotti FG, Stepp MA, Suzuki S, Engvall E, Ruoslahti E. (1992). Proteolytic processing of endogenous and recombinant β4 integrin subunit. J Cell Biol. 118(4):951-9.

Giancotti FG, Ruoslahti E. (1990). Elevated levels of the α5β1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell. 60(5):849-59.

Giancotti FG, Comoglio PM, Tarone G, (1986). A 135,000-mol-wt plasma membrane glycoprotein involved in fribronectin-mediated cell adhesion: immunfluorescence localization in normal and RSV-transformed fibroblasts. Exp. Cell Res. 163:47-62.

Giancotti FG, Tarone G. Knudsen K, Damsky C, Comoglio PM. (1985). Cleavage of a 135 Kd cell surface glycoprotein correlates with the loss of fibroblast adhesin to fibronectin. Exp. Cell Res. 156:182-190.

Review Articles

Cooper J, Giancotti FG. (2014). Molecular insights into NF2/Merlin tumor suppressor function. FEBS Lett. April 12.

Giancotti FG. (2014). Deregulation of the cell signaling in cancer. FEBS Lett. Feb 20.

Giancotti FG. (2013). Mechanisms governing metastatic dormancy and reactivation. Cell. Nov 7;155(4):750-64.

Ladanyi M, Zauderer MG, Krug LM, Ito T, McMillan R, Bott M, Giancotti FG. (2012). New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. Clin Cancer Res. Sep 1;18(17)4485-90.

Li W, Cooper J, Karajannis MA, Giancotti FG. (2012). Merlin: a tumor suppressor with functions at the cell cortex and in the nucleus. EMBO Rep. Mar;13(3):204-15.

Huson SM, Acosta MT, Belzberg AJ, Bernards A, Chernoff J, Cichowski K, Gareth Evans D, Ferner RE, Giovannini M, Korf BR, Listernick R, North KN, Packer RJ, Parada LF, Peltonen J, Ramesh V, Reilly KM, Risner JW, Schorry EK, Upadhyaya M, Viskochil DH, Zhu Y, Hunter-Schaedle K, Giancotti FG. (2011). Back to the future: Proceedings from the 2010 NF Conference. Am J Med Genet A. 155(2):307-21.

Li W, Giancotti FG. (201). Merlin's tumor suppression linked to inhibition of the E3 ubiquitin ligase CRL4 (DCAF1). Cell Cycle 9(22):4433-36.

Okada T, You L, Giancotti FG. (2207). Shedding light on Merlin's wizardry. Trends Cell Biol. May;17(5):222-29.

Pylayeva Y, Giancotti FG. (2007). Tensin releif facilitates migration. Nat cell Biol Aug; 9(8):877-9.

Giancotti FG. (2007). Targeting integrin beta4 for cancer and anti-angiogenic therapy. Trends Pharmacol Sci. Oct;28(10):506-11.

Guo W, Giancotti FG. (2204). Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. Oct; 5(10):816-26.

Giancotti FG, Tarone G. (2203). Positional control of cell fate through joint integrin/receptor protein kinase signaling. Annu Rev Cell Dev Biol. 19:173-206.

Giancotti FG. (2003). A structural view of integrin activation and signaling. Dev Cell. Feb 4(2):149-51.

Giancotti FG. (2000). Complexity and specificity of integrin signalling. Nat Cell Biol. Jan;2(1):E13-4.

Giancotti FG, Ruoslahti E. (1999). Integrin signaling. Science Aug 285(5430):1028-32.

Giancotti FG. (1997). Integrin signaling: specificity and control of cell survival and cell cycle progression. Curr Opin Cell Biol. Oct;9(5):691-700.